PRODUCT MONOGRAPH

PrRENVELA®

sevelamer carbonate tablets
800 mg

sevelamer carbonate powder for oral suspension

Powder, 0.8 g and 2.4 g

Phosphate Binder

ATC code: VO3A EO2
<table>
<thead>
<tr>
<th>Table of Contents</th>
</tr>
</thead>
<tbody>
<tr>
<td>PART I: HEALTH PROFESSIONAL INFORMATION .......................................................... 3</td>
</tr>
<tr>
<td>SUMMARY PRODUCT INFORMATION ........................................................................ 3</td>
</tr>
<tr>
<td>INDICATIONS AND CLINICAL USE ........................................................................ 3</td>
</tr>
<tr>
<td>CONTRAINDICATIONS ........................................................................................ 4</td>
</tr>
<tr>
<td>WARNINGS AND PRECAUTIONS ........................................................................... 4</td>
</tr>
<tr>
<td>ADVERSE REACTIONS ....................................................................................... 6</td>
</tr>
<tr>
<td>DRUG INTERACTIONS ....................................................................................... 8</td>
</tr>
<tr>
<td>DOSAGE AND ADMINISTRATION ....................................................................... 9</td>
</tr>
<tr>
<td>OVERDOSAGE ................................................................................................ 13</td>
</tr>
<tr>
<td>ACTION AND CLINICAL PHARMACOLOGY ....................................................... 13</td>
</tr>
<tr>
<td>STORAGE AND STABILITY .............................................................................. 14</td>
</tr>
<tr>
<td>SPECIAL HANDLING INSTRUCTIONS .............................................................. 14</td>
</tr>
<tr>
<td>DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................... 14</td>
</tr>
<tr>
<td>PART II: SCIENTIFIC INFORMATION .................................................................. 16</td>
</tr>
<tr>
<td>PHARMACEUTICAL INFORMATION ..................................................................... 16</td>
</tr>
<tr>
<td>CLINICAL TRIALS .......................................................................................... 17</td>
</tr>
<tr>
<td>DETAILED PHARMACOLOGY .......................................................................... 21</td>
</tr>
<tr>
<td>TOXICOLOGY ................................................................................................ 22</td>
</tr>
<tr>
<td>PART III: CONSUMER INFORMATION .............................................................. 26</td>
</tr>
</tbody>
</table>
**PRENVELA®**

Sevelamer carbonate tablet and sevelamer carbonate powder for oral suspension

**PART I: HEALTH PROFESSIONAL INFORMATION**

**SUMMARY PRODUCT INFORMATION**

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Dosage Form/Strength</th>
<th>All Nonmedicinal Ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td>Tablet 800 mg</td>
<td>Diacetylated monoglycerides, hypromellose, iron oxide black, isopropyl alcohol, microcrystalline cellulose, propylene glycol, sodium chloride, zinc stearate. <em>For a complete listing see Dosage Forms, Composition and Packaging section.</em></td>
</tr>
<tr>
<td>Oral</td>
<td>Powder 0.8 g, and 2.4 g</td>
<td>Natural and artificial citrus cream flavour, propylene glycol alginate, sodium chloride, sucralose, and ferric oxide (yellow). <em>For a complete listing see Dosage Forms, Composition and Packaging section.</em></td>
</tr>
</tbody>
</table>

**INDICATIONS AND CLINICAL USE**

- RENVELA (sevelamer carbonate) is indicated for the control of hyperphosphatemia in adult and pediatric patients (≥6 years of age and a Body Surface Area (BSA) of ≥0.75 m²) with end-stage renal disease (ESRD) undergoing dialysis.

**Pediatrics (6 - <18 years of age)**
Based on the data submitted and reviewed by Health Canada, the safety and efficacy of RENVELA has been established in children ≥6 years of age with a BSA ≥0.75 m² who have ESRD and are undergoing dialysis; therefore, Health Canada has authorized an indication for pediatric use in this population. RENVELA is not recommended for use in children that are below 6 years of age, have a BSA below 0.75 m², or that have mild hyperphosphatemia (see WARNINGS AND PRECAUTIONS, Special Populations, and CLINICAL TRIALS).

**Geriatrics (≥ 65 years of age):**
Evidence from clinical studies suggests that lower doses of sevelamer carbonate powder could be sufficient to normalize serum phosphate levels in elderly patients (≥65 years of age). Cautious monitoring and titration practices are recommended (see WARNINGS AND PRECAUTIONS, Special Populations, and CLINICAL TRIALS).
CONTRAINDICATIONS

RENVELA (sevelamer carbonate) is contraindicated in the following situations:

- patients with hypophosphatemia
- patients with bowel obstruction, or known active mucosal injury such as necrosis, perforation, ulcerative colitis or gastrointestinal bleeding (see WARNINGS AND PRECAUTIONS section).
- patients hypersensitive to sevelamer or one of the other ingredients in the product.

WARNINGS AND PRECAUTIONS

SERIOUS WARNINGS AND PRECAUTIONS

Serious cases of dysphagia, bowel obstruction, and perforation, have been associated with RENVELA use, some requiring hospitalization and surgery.

General

Patients with renal insufficiency may develop hypocalcemia. As RENVELA does not contain calcium, serum calcium levels should be monitored and elemental calcium should be supplemented whenever considered necessary. In cases of hypocalcemia, patients should be given an evening calcium supplement.

Caution should be exercised to avoid hypophosphatemia, a serum phosphorus of < 0.8 mmol/L (see DOSAGE AND ADMINISTRATION).

Rare serious case reports of difficulty swallowing the RENVELA tablet have been reported. Many of these cases involved patients with contributing co-morbid conditions affecting the ability to swallow including swallowing disorders or oesophageal abnormalities. Caution should be exercised when RENVELA tablets are used in these patients. Consider using powder for oral suspension in patients with a history of difficulty swallowing and in pediatric patients.

Sevelamer binds to bile acids and, therefore, prevents cholesterol absorption.

The safety and efficacy of RENVELA in patients with renal disease who are not undergoing dialysis has not been established.

Gastrointestinal

Cases of dysphagia and oesophageal tablet retention have been reported in association with use of the tablet formulation of RENVELA, some requiring hospitalization and intervention.

Cases of bowel obstruction (ileus, subileus) and perforation have also been reported with RENVELA use. Constipation may be a preceding symptom.
Patients with dysphagia, swallowing disorders, severe gastrointestinal (GI) motility disorders including severe constipation, or major GI tract surgery were not included in the RENVELA clinical studies.

The safety and efficacy of RENVELA in patients with dysphagia, swallowing disorders, severe GI motility disorders including severe constipation, or major GI tract surgery have not been established. Caution should be exercised when RENVELA is used in patients with these GI disorders. These patients should be monitored carefully while being treated with RENVELA. RENVELA treatment should be re-evaluated in patients who develop severe constipation or other severe GI symptoms (see ADVERSE REACTIONS).

Cases of serious inflammatory disorders of the gastrointestinal tract (with complications including hemorrhage, perforation, ulceration, necrosis, colitis, and colonic/cecal mass) associated with the presence of sevelamer crystals have been reported (see Post-Market Adverse Drug Reactions). Inflammatory disorders may resolve upon RENVELA discontinuation. Treatment discontinuation should be considered in patients who develop severe gastrointestinal symptoms (see CONTRAINDICATIONS and ADVERSE REACTIONS sections).

**Special Populations**

**Pregnant Women:** The safety of RENVELA has not been established in pregnant women. In preclinical studies, there was no evidence that sevelamer induced embryolethality, fetotoxicity or teratogenicity at the doses tested (up to 1 g/kg/day in rabbits; up to 4.5 g/kg/day in rats). RENVELA should only be given to pregnant women if the benefits outweigh the risks.

**Nursing Women:** There have been no adequate, well-controlled studies in nursing women; however, since sevelamer is not absorbed, excretion in breast milk is not expected.

**Pediatrics:** The safety and efficacy of RENVELA in pediatrics was evaluated in a clinical trial with hyperphosphatemic children that were ≥6 years of age, had a BSA ≥0.75 m², and were mostly in ESRD undergoing dialysis. RENVELA was apparently less effective in children with a mildly elevated age-appropriate serum phosphorus level (<2.26 mmol/L), which typically described adolescents not on dialysis at screening (see CLINICAL TRIALS). The safety profile in pediatrics was similar to that described for adults (see ADVERSE REACTIONS, Clinical Trial Adverse Drug Reactions). RENVELA is not recommended for use in children that are below 6 years of age, have a BSA below 0.75 m², or that have mild hyperphosphatemia. Warnings applicable to adults are also relevant for pediatrics.

**Geriatrics: (≥ 65 years of age):** In one clinical trial in adults undergoing hemodialysis, patients ≥65 years old (n=5) attained lower serum phosphorus levels compared to patients <65 years old, even if taking lower doses of RENVELA powder for oral suspension. Careful monitoring and gradual titration practices are recommended for geriatric patients in order to reduce the risk of hypophosphatemia (see CLINICAL TRIALS).

**Monitoring and Laboratory Tests**

Bicarbonate and chloride levels should be monitored.
Monitor for reduced vitamins D, E, K and folic acid levels. In preclinical studies in rats and dogs, sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate, reduced vitamins D, E and K, and folic acid levels at doses 6-10 times the recommended human dose. In short-term clinical trials, there was no evidence of reduction of serum levels of vitamins. However, in a one-year clinical trial, 25-hydroxyvitamin D (normal range 10 to 55 ng/mL) fell from 39±22 to 34±22 ng/mL (p<0.01) with sevelamer hydrochloride treatment. Most (approximately 75%) patients in sevelamer hydrochloride clinical trials received vitamin supplements which is typical of patients on dialysis.

ADVERSE REACTIONS

Clinical Trial Adverse Drug Reactions

Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

There are limited data on the safety of RENVELA (sevelamer carbonate). However, because it contains the same active ingredient as the hydrochloride salt, the adverse event profiles of the two salts should be similar. In a cross-over study in patients undergoing hemodialysis with treatment duration of eight weeks each and without a mid-point washout period, the adverse reactions on sevelamer carbonate were similar to those observed on sevelamer hydrochloride.

In long-term studies with sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate, the most common adverse events included: vomiting, nausea, diarrhea, dyspepsia, abdominal pain, flatulence and constipation as shown in Table 1. Most frequently occurring treatment related adverse events for RENVELA powder in a short term (4-week cross-over) study were: nausea, constipation and vomiting. During the pediatric study, with the use of sevelamer carbonate tablets and powder, most of adverse events reported as related or possibly related to sevelamer carbonate were gastrointestinal in nature. In general, the adverse event profile for the pediatric population evaluated in the study was similar to the profile observed in adults (see CLINICAL TRIALS).

Based on studies of 8-52 weeks, the most common reasons for withdrawal from sevelamer hydrochloride were gastro-intestinal adverse reactions (3-16%).

In a combined safety database comprised of 483 patients with ESRD undergoing hemodialysis, adverse events reported at an incidence ≥10% are provided in Table 1 below. From this database, adverse events are also presented separately from a single long-term randomized clinical study for sevelamer hydrochloride and calcium. The adverse events presented in the table below are not necessarily attributed to sevelamer hydrochloride treatment. The incidence of these events was not dose related.
Table 1: Adverse Events in Patients with End-Stage Renal Disease undergoing Hemodialysis

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Total AEs reported</th>
<th>52 weeks Study of sevelamer hydrochloride vs. calcium (calcium acetate and calcium carbonate)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>sevelamer hydrochloride</td>
<td>sevelamer hydrochloride</td>
<td>calcium</td>
</tr>
<tr>
<td></td>
<td>N = 483</td>
<td>N = 99</td>
<td>N = 101</td>
</tr>
<tr>
<td>Gastrointestinal Disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vomiting</td>
<td>24.4</td>
<td>22.2</td>
<td>21.8</td>
</tr>
<tr>
<td>Nausea</td>
<td>25.3</td>
<td>20.2</td>
<td>19.8</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>21.1</td>
<td>19.2</td>
<td>22.8</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>15.7</td>
<td>16.2</td>
<td>6.9</td>
</tr>
<tr>
<td>Constipation</td>
<td>13.3</td>
<td>8.1</td>
<td>11.9</td>
</tr>
<tr>
<td>Infections and Infestations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>13.9</td>
<td>14.1</td>
<td>7.9</td>
</tr>
<tr>
<td>Bronchitis</td>
<td>5.4</td>
<td>11.1</td>
<td>12.9</td>
</tr>
<tr>
<td>Upper Respiratory Tract Infection</td>
<td>7.0</td>
<td>5.1</td>
<td>10.9</td>
</tr>
<tr>
<td>Musculoskeletal, Connective Tissue and Bone Disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain in Limb</td>
<td>13.7</td>
<td>13.1</td>
<td>14.9</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>11.4</td>
<td>12.1</td>
<td>17.8</td>
</tr>
<tr>
<td>Back Pain</td>
<td>6.0</td>
<td>4.0</td>
<td>17.8</td>
</tr>
<tr>
<td>Skin Disorders</td>
<td>10.4</td>
<td>13.1</td>
<td>9.9</td>
</tr>
<tr>
<td>Respiratory, Thoracic and Mediastinal Disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dyspnea</td>
<td>15.7</td>
<td>10.1</td>
<td>16.8</td>
</tr>
<tr>
<td>Cough</td>
<td>11.6</td>
<td>7.1</td>
<td>12.9</td>
</tr>
<tr>
<td>Vascular Disorders</td>
<td>9.3</td>
<td>10.1</td>
<td>5.9</td>
</tr>
<tr>
<td>Hypertension</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nervous System Disorders</td>
<td>18.4</td>
<td>9.1</td>
<td>15.8</td>
</tr>
<tr>
<td>General Disorders and Site Administration Disorders</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dialysis Access Complication</td>
<td>4.3</td>
<td>6.1</td>
<td>10.9</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>8.7</td>
<td>5.1</td>
<td>10.9</td>
</tr>
</tbody>
</table>

In 143 patients with ESRD undergoing peritoneal dialysis with treatment duration of 12 weeks (97 on sevelamer hydrochloride and 46 on a calcium-based product), the safety profile was similar to that reported for hemodialysis patients except for peritonitis which is a known complication in these patients.

**Post-Market Adverse Drug Reactions**

The following adverse reactions have been identified during post-approval use of sevelamer hydrochloride (which has the same active moiety as RENVELA): allergic reactions including angioedema, anaphylaxis (some fatal) and erythema, hypersensitivity vasculitis, pruritus, rash, abdominal pain, fecal impaction, and uncommon cases of intestinal obstruction, ileus, subileus and intestinal perforation. Cases of diverticulitis were also reported.
Cases of serious inflammatory disorders of the gastrointestinal tract (with complications including hemorrhage, perforation, ulceration, necrosis, colitis, and intestinal mass) associated with the presence of sevelamer crystals have been reported (see CONTRAINDICATIONS and WARNINGS and PRECAUTIONS).

Cases of gastrointestinal mucosal necrosis, gastrointestinal bleeding, and colitis associated with the presence of sevelamer crystals have been reported. However, the causality of the sevelamer crystals in initiating such disorders has not been demonstrated (see CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS sections).

DRUG INTERACTIONS

Drug-Drug Interactions
Sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate, has been studied in human drug-drug interaction studies. In interaction studies in healthy volunteers, sevelamer hydrochloride had no effect on the bioavailability of a single-dose of digoxin, warfarin, enalapril, metoprolol or iron.

However, the bioavailability of ciprofloxacin was decreased by approximately 50% when co-administered with sevelamer hydrochloride in a single dose study. Consequently, sevelamer hydrochloride (and thus sevelamer carbonate) should not be taken simultaneously with ciprofloxacin.

During postmarketing experience, reduced concentrations of cyclosporin, mycophenolate mofetil and tacrolimus have been reported in transplant patients when co-administered with sevelamer hydrochloride. The possibility of an interaction cannot be excluded and close monitoring of blood concentrations of cyclosporin, mycophenolate mofetil and tacrolimus or dosing these medicines apart from RENVELA to prevent GI binding (at least one hour before or three hours after RENVELA) should be considered during the use of any of these agents in combination with RENVELA and after its withdrawal.

During postmarketing experience, very rare cases of increased thyroid stimulating hormone (TSH) levels have been reported in patients co-administered sevelamer hydrochloride and levothyroxine. Closer monitoring of TSH levels is therefore recommended in patients receiving both medications.

During postmarketing experience, very rare cases of increased phosphate levels have been reported in patients taking proton pump inhibitors co-administered with sevelamer carbonate.

When administering an oral medication where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy, the drug should be administered at least one hour before or three hours after sevelamer carbonate, or the physician should consider monitoring blood levels of the drug. Patients taking anti-arrhythmic medications for the control of arrhythmias and anti-seizure medications for the control of seizure disorders were excluded from the clinical trials. Special precautions should be taken when prescribing sevelamer carbonate to patients also taking these medications.

Drug-Food Interactions
There have been no adequate, well-controlled studies regarding the effect of a variety of foods on the intestinal phosphorus binding of sevelamer. In all clinical studies patients were instructed to take sevelamer with meals.

**Drug-Herb Interactions**

There have been no adequate, well-controlled studies regarding drug-herb interactions.

**Drug-Laboratory Interactions**

There have been no adequate, well-controlled studies regarding drug-laboratory interactions.

**Drug-Lifestyle Interactions**

There have been no adequate, well-controlled studies regarding drug-lifestyle interactions.

**DOSAGE AND ADMINISTRATION**

**Dosing Considerations**

- RENVELA (sevelamer carbonate) is available as tablets or powder for oral suspension. The formulation administered may be based on patient preference; however, a mixture of tablets and powder is not recommended. In the pediatric study, children with a BSA ≥0.75 to <1.2 m² were administered only the powder formulation (see CLINICAL TRIALS). As tablets may present a choking hazard to small children, RENVELA powder for oral suspension is recommended for children with a BSA <1.2 m² (see Recommended Dose and Dosage Adjustment; Pediatrics).
- RENVELA tablets should not be bitten, chewed or broken apart prior to dosing.
- RENVELA should be taken with meals, since its action is to bind ingested phosphate (see ACTION AND CLINICAL PHARMACOLOGY, Mechanism of Action)
- When administering any other medication where a reduction in the bioavailability of that medication would have a clinically significant effect on safety or efficacy, the physician should consider monitoring blood levels or dosing that medicine apart from RENVELA to prevent GI binding (at least one hour before or three hours after RENVELA).
- Monitor serum phosphorus, and adjust the dose of RENVELA based on the desired target range (see Recommended Dose and Dosage Adjustment; Adults, Pediatrics).

**Recommended Dose and Dosage Adjustment**

**Tablets**

RENEWLA 800 mg tablets should be taken three times per day with meals at a dosage based on individual patient requirements to control serum phosphate levels (see dosing recommendations for Adults and Pediatrics below).

**Powder for oral suspension**
RENVELA 0.8 g or 2.4 g powder sachets should be taken three times per day with meals. RENVELA powder sachets can be combined to achieve the required dose to control serum phosphate levels. The recommended amount of water per sachet must be used for reconstitution (see DOSAGE AND ADMINISTRATION, Reconstitution of Sevelamer Powder for Oral Suspension).

**Adults (≥18 years of age):**

The recommended dosing to be used when initiating RENVELA in adult patients not using another phosphate binder is outlined below in Table 2. Patients may take either tablets or powder for oral suspension at each dosing period, according to preference. For powder for oral suspension reconstitution instructions, including how to prepare a required dose from multiple sachets, see **Reconstitution of Sevelamer powder for oral suspension** below.

**Table 2: Starting Dose for Dialysis Patients Not Taking a Phosphate Binder**

<table>
<thead>
<tr>
<th>Initial Serum Phosphorus</th>
<th>RENVELA 800 mg tablet</th>
<th>RENVELA powder</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt; 1.8 and &lt; 2.4 mmol/L</td>
<td>1 tablet three times a day with meals (2.4 grams/day)</td>
<td>0.8 g three times a day with meals (2.4 grams/day)</td>
</tr>
<tr>
<td>≥ 2.4 mmol/L</td>
<td>2 tablets three times a day with meals (4.8 grams/day)</td>
<td>1.6 g three times a day with meals (4.8 grams/day)</td>
</tr>
</tbody>
</table>

For patients previously on sevelamer hydrochloride, RENVELA should be given on a gram for gram basis with monitoring of serum phosphorus levels to ensure optimal daily doses.

In a study in 84 chronic kidney disease (CKD) patients on hemodialysis, a similar reduction in serum phosphorus was seen with equivalent doses (approximately mg for mg) of sevelamer hydrochloride and calcium acetate. Table 3 gives recommended starting doses of RENVELA based on a patient’s current calcium acetate dose.

**Table 3. Starting Dose for Dialysis Patients Switching From Calcium Acetate to RENVELA**

<table>
<thead>
<tr>
<th>Calcium Acetate 667 mg (Tablets per meal)</th>
<th>RENVELA 800 mg Tablet (Tablets per meal)</th>
<th>RENVELA powder (grams per meal)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 tablet</td>
<td>1 tablet</td>
<td>0.8 g</td>
</tr>
<tr>
<td>2 tablets</td>
<td>2 tablets</td>
<td>1.6 g</td>
</tr>
<tr>
<td>3 tablets</td>
<td>3 tablets</td>
<td>2.4 g</td>
</tr>
</tbody>
</table>

Dose adjustments, when necessary should be done every 1 to 3 weeks by increasing one tablet per meal (3 tablets per day) or 0.8 grams of powder per meal (2.4 grams per day) until the desired serum levels are met.

The total dose should be divided according to the meal portion during the day.
Pediatric patients (6 - <18 years of age):

The recommended starting dose for pediatric patients is based on the patient’s Body Surface Area (BSA) category (Table 4). The body surface area can be calculated using the Gehan & George body surface area equation:

$$BSA = 0.0235 \cdot h^{0.42246} \cdot w^{0.51456}$$

BSA is in m², w is the weight of the person in kg, and h is the height of the person in cm.

The powdered formulation is recommended for children with a BSA ≥0.75 to <1.2 m², whereas children with a BSA ≥1.2 m² may take either powder or tablets, according to preference. For powder for oral suspension reconstitution instructions, including how to prepare a required dose for titrations or from multiple sachets, see Reconstitution of Sevelamer powder for oral suspension below.

RENVELA should be taken three times per day with meals and/or snacks. If a pediatric patient eats less than 3 meals/snacks per day, RENVELA should only be given per meal/snack and not on an empty stomach. For example, if the patient's screening BSA is ≥0.75 to <1.2 m² and the patient eats 2 meals/snacks per day, that patient will take 0.8 g BID with meals.

<table>
<thead>
<tr>
<th>BSA (m²)</th>
<th>Dose per Meal / Snack</th>
<th>Titration increases / decreases</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥0.75 to &lt;1.2</td>
<td>0.8 g powder three times daily</td>
<td>Titrate up / down by 0.4 g three times daily</td>
</tr>
<tr>
<td>≥1.2</td>
<td>1.6 g powder or tablets three times daily</td>
<td>Titrate up / down by 0.8 g three times daily</td>
</tr>
</tbody>
</table>

Perform dose adjustments when necessary according to the BSA category up/down titration dosage quantities listed in Table 4. Titrate in two week intervals for the first 6 weeks, and then every 4 weeks as needed to obtain the desired serum phosphorus target.

**Reconstitution of Sevelamer Powder for Oral Suspension**

RENVELA powder is available in 0.8 or 2.4 g sachets. The entire contents of each 0.8 g or 2.4 g sachet should be placed in a cup and mixed thoroughly with the amount of water, described in Table 5, until powder is fully dispersed. The patient should be informed that the powder does not dissolve. Multiple sachets may be mixed at once in order to prepare a required dose, as long as the total recommended volume of water is used (as per table 5). For increments of 0.4 g, use one half of a 0.8 g sachet (see instructions below).
Table 5. RENVELA Powder Preparation Instructions

<table>
<thead>
<tr>
<th>RENVELA Powder Required Doses</th>
<th>Minimum amount of water for dose preparation (mL / tablespoons)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.4 g</td>
<td>30 mL / 2 tablespoons</td>
</tr>
<tr>
<td>0.8 g</td>
<td>30 mL / 2 tablespoons</td>
</tr>
<tr>
<td>2.4 g</td>
<td>60 mL / 4 tablespoons</td>
</tr>
</tbody>
</table>

For increments of 0.4 g and to achieve the correct dose, a 0.8 g sachet of RENVELA powder may be divided. The RENVELA powder may be measured by volume (mL) using a measuring scoop or measuring spoon (Table 6). Further instructions are detailed in the patient leaflet.

Table 6. RENVELA Powder Preparation Instructions for increments of 0.4 g

<table>
<thead>
<tr>
<th>Sevelamer carbonate dose (g)</th>
<th>Volume of powder (mL spoon or teaspoon amount)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.4 g (400 mg)</td>
<td>1 mL spoon or ¼ teaspoon</td>
</tr>
<tr>
<td>0.8 g (800 mg)</td>
<td>2 mL spoon or ½ teaspoon</td>
</tr>
</tbody>
</table>

As an alternative to water, the powder may be mixed with a small amount of cold beverage or food (e.g. 120 mL of beverage or food per 0.8 g or 2.4 g powder sachet) or added to lukewarm foods after cooking (up to 50°C). Foods and beverages that have been assessed were ginger ale, oatmeal, applesauce, whey protein powder, scrambled eggs, and baked boneless-skinless chicken breast.

Do not heat RENVELA powder (e.g., microwave or any other heating source) or add to hot (>50°C) foods or liquids.

**Administration**

RENVELA powder preparations made with water or food should be entirely consumed within 30 min after preparation (liquid preparations should be re-suspended before drinking). Tablets should be swallowed intact and should not be crushed, chewed, or broken into pieces prior to administration.

**Maintenance**

Serum phosphorus should be monitored on a regular basis with the goal of maintaining serum phosphorus levels consistent with current medical standards (see Dosing Considerations).

In clinical trials, the average actual daily dose of sevelamer carbonate, in adults, was approximately 6 g per day. The highest studied daily dose of sevelamer carbonate taken was 14.4 g per day in adult CKD patients. There was limited clinical trial experience in children with a BSA <1.2 m² that exceeded 6 g/day and in children with a BSA ≥1.2 m² that exceeded 10 g/day.
Missed Dose

- If a dose is forgotten, it should be skipped. Double dosing is not advisable.

OVERdosAGE

In adult CKD patients on dialysis, the maximum dose studied was 14.4 grams of sevelamer carbonate and 13 grams of sevelamer hydrochloride. Sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate, has been given to normal healthy adult volunteers in doses of up to 14.4 grams per day for eight days with no adverse effects. There are no reports of overdosage with sevelamer carbonate or sevelamer hydrochloride in patients. Since sevelamer is not absorbed, the risk of systemic toxicity is low.

ACTION AND CLINICAL PHARMACOLOGY

Patients with chronic kidney disease (CKD) retain phosphorus and can develop hyperphosphatemia. High serum phosphorus can precipitate serum calcium resulting in ectopic calcification. When the product serum calcium and phosphorus concentrations (Ca x P) exceeds 4.4 mmol/L, there is an increased risk that ectopic calcification will occur. Hyperphosphatemia plays a role in the development of secondary hyperparathyroidism in renal insufficiency. An increase in parathyroid hormone (PTH) levels is characteristic of patients with chronic renal failure. Increased levels of PTH can lead to osteitis fibrosa. A decrease in serum phosphorus may decrease serum PTH levels.

Mechanism of Action

Sevelamer carbonate is a non-absorbed phosphate binding crosslinked polymer, free of metal and calcium. It contains multiple amines separated by one carbon from the polymer backbone. These amines exist in a protonated form in the intestine and interact with phosphate molecules through ionic and hydrogen bonding. By binding phosphate in the dietary tract and decreasing absorption, sevelamer carbonate lowers the phosphate concentration in the serum.

In addition to effects on serum phosphate levels, sevelamer hydrochloride has been shown to bind bile acids in vitro and in vivo in experimental animal models. Because sevelamer binds bile acids, it may interfere with normal fat absorption and thus may reduce absorption of fat soluble vitamins such as A, D and K as well as other substances such as cholesterol.

In vitro equilibrium studies demonstrated that sevelamer hydrochloride tablets, sevelamer carbonate tablets and sevelamer carbonate powder were equivalent in terms of phosphate binding, with and without acid pre-treatment. Kinetic experiments demonstrated that sevelamer carbonate and sevelamer hydrochloride tablets bind phosphate in a similarly rapid manner. Therefore, these in vitro studies have shown that sevelamer carbonate and sevelamer hydrochloride are equivalent in their phosphate binding properties.
Sevelamer does not contain calcium and decreases the incidence of hypercalcaemic episodes as compared to patients using calcium based phosphate binders alone. The effects of sevelamer on phosphorus and calcium were proven to be maintained throughout a study with one year follow-up.

**Pharmacokinetics**

Pharmacokinetic studies have not been carried out with sevelamer carbonate or sevelamer hydrochloride as sevelamer is not absorbed from the GI tract, as confirmed by an absorption study in healthy volunteers. In this study a mass balance study using $^{14}$C-sevelamer hydrochloride in 16 healthy male and female volunteers showed that sevelamer hydrochloride is not systemically absorbed. No absorption studies have been performed in patients with renal disease.

**STORAGE AND STABILITY**

Store at controlled room temperature 15°C to 30°C. Protect from moisture and heat.

**SPECIAL HANDLING INSTRUCTIONS**

None.

**DOSAGE FORMS, COMPOSITION AND PACKAGING**

**RENVELA tablets**

RENVELA 800 mg tablets are supplied as white, oval, film-coated, tablets, imprinted with “RENVELA 800”, containing 800 mg of sevelamer carbonate on an anhydrous basis, microcrystalline cellulose, sodium chloride, zinc stearate and coating components hypromellose and diacetylated monoglycerides. The tablet printing ink also contains hypromellose in addition to iron oxide black, propylene glycol, isopropyl alcohol.

RENVELA 800 mg tablets are available in bottles of 180 tablets.

RENVELA tablets are packaged in white high-density polyethylene bottles (HDPE), with a child resistant polypropylene cap and an induction seal.
RENVELA powder

RENVELA sachets are supplied as powder for oral suspension containing 0.8 g or 2.4 g of sevelamer carbonate on an anhydrous basis, natural and artificial citrus cream flavouring, propylene glycol alginate, sodium chloride, sucralose, and ferric oxide (yellow). Each sachet is opaque, foil lined, and heat sealed.

RENVELA 0.8 g sachets are packaged in boxes of 90 count sachets.

RENVELA 2.4 g sachets are packaged in boxes of 90 count sachets.
PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Common name: Sevelamer carbonate (USAN)

Chemical names:
1. poly(allylamine-co-N,N' -diallyl-1,3-diamino-2-hydroxypropane) carbonate salt (CAS)
2. Oxirane, (chloromethyl)-, polymer with 2-propen-1-amine, carbonate salt (CAS)
3. 2-Propen-1-amine, polymer with (chloromethyl) oxirane, carbonate salt (CAS)
4. Allylamine polymer with 1-chloro-2,3-epoxypropane, carbonate salt (IUPAC)

Molecular formula and molecular mass:

\[(\text{C}_3\text{H}_7\text{N}\cdot\text{nH}_2\text{CO}_3)^{810z}\cdot(\text{C}_9\text{H}_{18}\text{N}_2\text{O}\cdot\text{nH}_2\text{CO}_3)^{95z}\] where \(z\) = a large number.

Sevelamer carbonate is a highly cross-linked polymer of varying size, and each particle can be considered as one molecule. Since the molecular weight is equal to the weight of the particle itself, the molecular weight distribution of a cross-linked polymer is a function of the distribution of particle sizes.

Structural formula:

\[
\begin{align*}
\text{NH}_2^+ & \quad \text{HCO}_3^- \\
\text{NH} & \quad \text{OH} \\
\text{NH}_2 & \quad \text{NH}
\end{align*}
\]

\(a, b = \text{number of primary amine groups} \quad a + b = 9\)
\(c = \text{number of crosslinking groups} \quad c = 1\)
\(m = \text{large number to indicate extended polymer network}\)
Physicochemical properties:

**Description:** Sevelamer carbonate is a cross-linked poly(allylamine carbonate) polymer. The cross-linking agent is epichlorohydrin (1-chloro-2,3-epoxypropane). The cross-linking groups consist of two secondary amine groups derived from the starting material, poly(allylamine hydrochloride) and one molecule of epichlorohydrin giving 2-hydroxypropyl linkers. A portion of the amine is present as the carbonate salt, at 14 – 21% by weight; this is similar to sevelamer hydrochloride where the chloride salt is present at 15 – 20%, by weight.

**Physical Form:** White to off-white free flowing powder.

**Solubilities:** Insoluble in all tested solvents.

**Crystallinity:** Amorphous, granular.

**pH Values:** 8 – 10.5 (1% aqueous slurry).

**Hygroscopicity:** Sevelamer carbonate is hygroscopic.

**CLINICAL TRIALS**

The safety and efficacy of sevelamer to control serum phosphorus in CKD patients on dialysis was mainly determined by the ability of sevelamer hydrochloride to bind phosphorus from food in one double-blind and several open-label clinical trials in hemodialysis and peritoneal dialysis patients. Both tablet and powder formulations of sevelamer carbonate administered three times per day with meals have been shown to control serum phosphorus effectively.

In two double-blind, randomized, two 8-week period cross-over clinical trials in hemodialysis patients, sevelamer carbonate was shown to be therapeutically equivalent to sevelamer hydrochloride.

In the first study, 79 stage 5 CKD patients received, in a random order, sevelamer carbonate 800 mg tablet and sevelamer hydrochloride 800 mg tablets during each 8-week period without an intervening washout phase. The study dose during the cross-over period was based on the sevelamer hydrochloride given during the run-in period. The average actual dose divided among meals during the randomized treatment periods was 6.0 ± 2.8 g/day for both treatment regimens. There was no significant difference in mean serum phosphorus between the two groups during the treatment periods (1.5 ± 0.3 mmol/l during sevelamer carbonate treatment and 1.5±0.3 mmol/l during sevelamer hydrochloride treatment). Following a two-week washout phase after the end of the last period of the cross-over, phosphorus rose significantly to 2.1 ± 0.6 mmol/l.
In the second study, 21 hyperphosphatemic patients with CKD receiving hemodialysis 3 times per week received, in a random order, sevelamer hydrochloride tablets 800 mg and sevelamer carbonate powder 800 mg, each during a 4-week period without an intervening washout phase. The study dose during the cross-over period was based on the dose of sevelamer hydrochloride given during the run-in period. The average actual daily dose (divided between meals) administered during the randomized treatment periods was 5.9 ± 2.7 g for sevelamer carbonate powder and 6.5 ± 3.3 g for sevelamer hydrochloride tablets. This study demonstrated that sevelamer carbonate powder dosed three times per day with meals was equivalent in controlling serum phosphorus levels in hyperphosphatemic adults to sevelamer hydrochloride tablets dosed three times per day with meals (serum phosphorus time weighted averages were 1.6 ± 0.5 mmol/L for sevelamer carbonate powder and 1.7 ± 0.4 mmol/L for sevelamer hydrochloride tablets).

The ability of sevelamer hydrochloride to lower serum phosphorus in CKD patients on dialysis was demonstrated in six clinical trials: one double-blind placebo controlled 2-week study (sevelamer hydrochloride N=24); two open-label uncontrolled 8-week studies (sevelamer hydrochloride N=220) and three active-controlled open-label studies with treatment durations of 8 to 52 weeks (sevelamer hydrochloride N=256). Three of the active-controlled studies are described here. One is a crossover study with two 8-week periods comparing sevelamer hydrochloride to an active-control. The second is a 52-week parallel study comparing sevelamer hydrochloride with active-control. The third is a 12-week parallel study comparing sevelamer hydrochloride and active-control in peritoneal dialysis patients.

**Hemodialysis Patients**

**Active-Control, Cross-Over Study in Hemodialysis Patients**

Eighty-four CKD patients on hemodialysis who were hyperphosphatemic (serum phosphorus > 1.9 mmol/L) following a two-week phosphate binder washout period received sevelamer and active-control for eight weeks each in random order. Treatment periods were separated by a two-week phosphate binder washout period. Patients started on treatment three times per day with meals. Over each eight-week treatment period, at three separate time points the dose of sevelamer could be titrated up 1 capsule or tablet per meal (3 per day) to control serum phosphorus, the dose of active-control could also be altered to attain phosphate control. Both treatments significantly decreased mean serum phosphorus by about 0.6 mmol/L (Table 7).

<table>
<thead>
<tr>
<th></th>
<th>Sevelamer Hydrochloride (N=81)</th>
<th>Active Control (N=83)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline at End of Washout</td>
<td>2.7</td>
<td>2.6</td>
</tr>
<tr>
<td>Endpoint</td>
<td>2.1</td>
<td>1.9</td>
</tr>
<tr>
<td>Change from Baseline at Endpoint (95% Confidence Interval)</td>
<td>-0.6* (-0.8, -0.5)</td>
<td>-0.7* (-0.8, -0.5)</td>
</tr>
</tbody>
</table>

*p<0.0001, within treatment group comparison
The distribution of responses is shown in Figure 1. The distributions are similar for sevelamer hydrochloride and active control. The median response is a reduction of about 0.6 mmol/L in both groups. About 50% of subjects have reductions between 0.3 and 1.0 mmol/L.

**Figure 1. Percentage of patients (Y-axis) attaining a phosphorus reduction from baseline (mmol/L) at least as great as the value of the X-axis.**

Average daily sevelamer hydrochloride dose at the end of treatment was 4.9 g (range of 0.0 to 12.6 g).

**Active-Control, Parallel Study in Hemodialysis Patients**

Two hundred CKD patients on hemodialysis who were hyperphosphatemic (serum phosphorus >1.8 mmol/L) following a two-week phosphate binder washout period were randomized to receive sevelamer hydrochloride 800 mg tablets (N=99) or an active-control (N=101). The two treatments produced similar decreases in serum phosphorus. At week 52, using last-observation-carried-forward, sevelamer hydrochloride and active-control both significantly decreased mean serum phosphorus (Table 8).

**Table 8. Mean Serum Phosphorus (mmol/L) and Ion at Baseline and Change from Baseline to End of Treatment**

<table>
<thead>
<tr>
<th></th>
<th>Sevelamer HCl (N=94)</th>
<th>Active-Control (N=98)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phosphorus Baseline</td>
<td>2.4</td>
<td>2.4</td>
</tr>
<tr>
<td>Change from Baseline at Endpoint</td>
<td>-0.7</td>
<td>-0.6</td>
</tr>
<tr>
<td>Ca x Phosphorus Ion Product Baseline</td>
<td>5.7</td>
<td>5.5</td>
</tr>
<tr>
<td>Change from Baseline at Endpoint</td>
<td>-1.6</td>
<td>-1.1</td>
</tr>
</tbody>
</table>
Sixty-one percent of sevelamer hydrochloride patients and 73% of the control patients completed the full 52 weeks of treatment. **Figure 2**, a plot of the phosphorus change from baseline for the completers, illustrates the durability of response for patients who are able to remain on treatment.

**Figure 2. Mean Phosphorus Change from Baseline for Patients who Completed 52 Weeks of Treatment**

Average daily sevelamer hydrochloride dose at the end of treatment was 6.5 g (range of 0.8 to 13 g).

**Active-Control, Parallel Study in Peritoneal Dialysis Patients**

One hundred and forty-three patients on peritoneal dialysis who were hyperphosphatemic (serum phosphorus > 1.8 mmol/L) following a two-week phosphate binder washout period were randomized to receive sevelamer hydrochloride (N=97) or active-control (N=46) open label for 12 weeks. Average daily sevelamer hydrochloride dose at the end of treatment was 5.9 g (range 0.8 to 14.3 g). There were statistically significant changes in serum phosphorus (p<0.001) for sevelamer hydrochloride (-0.5 mmol/L from baseline of 2.4 mmol/L), similar to the active-control.

**Clinical Study of Sevelamer Carbonate Powder and Tablets in Pediatric Patients**

The safety and efficacy of sevelamer carbonate in hyperphosphatemic pediatric patients with Chronic Kidney Disease (CKD) was evaluated in a multicenter study with a 2-week, randomized, placebo-controlled, Fixed Dose Period (FDP) followed by a 6-month, single-arm, open-label, Dose Titration Period (DTP). A total of 101 patients (6 to 18 years old) with a Body Surface Area (BSA) range of 0.8 m² to 2.4 m² and hyperphosphatemia secondary to CKD were randomized in the study. Most patients were 13 to 18 years of age (73%), had a BSA ≥1.2 m² (84%), and were in ESRD (78%) undergoing dialysis (77%). Forty-nine (49) patients received sevelamer carbonate and 51 patients received placebo during the 2 week FDP; thereafter all patients received sevelamer carbonate for the 26-week Dose Titration Period (DTP).
The study met its primary and secondary efficacy endpoints. As the primary efficacy endpoint, sevelamer carbonate significantly reduced serum phosphorus through Week 2 of the FDP by an LS Mean difference of -0.29 (SE 0.087) mmol/L compared to placebo (p=0.001). The treatment response during the 2-week FDP was not affected by BSA. In contrast, no treatment response was observed in patients with a baseline serum phosphorus below 2.26 mmol/L or in patients that were not on dialysis (Figure 3). A similar treatment response was observed in patients who received sevelamer carbonate during the 6-month open-label DTP At the end of the DTP (week 28), 27% of patients on sevelamer carbonate reached their age-appropriate normal serum phosphorus levels, and children with a BSA <1.2 m² and a BSA ≥1.2 m² were prescribed a mean daily dose of approximately 4 g and 7 g, respectively. Most of the treatment emergent adverse events reported as related, or possibly related to sevelamer carbonate were gastrointestinal disorders such as nausea, constipation, vomiting, and abdominal pain. No new safety signals were identified during the study.

**Figure 3. Change in Serum Phosphorus (mmol/L) from Baseline to Week 2 of the FDP by Subgroup**

<table>
<thead>
<tr>
<th>Subgroup</th>
<th>N(%)</th>
<th>LS Mean Diff[a]</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>97 (100.0)</td>
<td>-0.29</td>
<td>(-0.47, -0.12)</td>
</tr>
<tr>
<td>Screening BSA (m²2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;1.2</td>
<td>14 (14.4)</td>
<td>-0.41</td>
<td>(-1.14, 0.32)</td>
</tr>
<tr>
<td>&gt;=1.2</td>
<td>83 (85.6)</td>
<td>-0.28</td>
<td>(-0.46, -0.10)</td>
</tr>
<tr>
<td>Baseline Serum Phosphorus (mmol/L)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;2.26</td>
<td>49 (50.5)</td>
<td>-0.03</td>
<td>(-0.25, 0.18)</td>
</tr>
<tr>
<td>&gt;=2.26</td>
<td>48 (49.5)</td>
<td>-0.54</td>
<td>(-0.81, -0.27)</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;13</td>
<td>26 (26.8)</td>
<td>-0.11</td>
<td>(-0.50, 0.28)</td>
</tr>
<tr>
<td>&gt;=13</td>
<td>71 (73.2)</td>
<td>-0.37</td>
<td>(-0.58, -0.16)</td>
</tr>
<tr>
<td>On Dialysis</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>74 (76.3)</td>
<td>-0.37</td>
<td>(-0.59, -0.15)</td>
</tr>
<tr>
<td>No</td>
<td>23 (23.7)</td>
<td>0.03</td>
<td>(-0.15, 0.22)</td>
</tr>
</tbody>
</table>

Note: LS Mean difference of Sevelamer Carbonate – Placebo, based on ANCOVA within subgroup and with treatment as fixed effect and screening BSA and baseline serum phosphorus as covariates.

**DETAILED PHARMACOLOGY**

Several *in vitro* assays and animal models were employed to evaluate the activity and efficacy of sevelamer. *In vitro* equilibrium and kinetic binding studies comparing sevelamer hydrochloride tablets (800 mg), sevelamer carbonate tablets (800 mg), and sevelamer carbonate powder (0.8 g,
1.6 g, and 2.4 g sachets) were conducted to compare key parameters of phosphate binding under varying physiologically relevant conditions that might be encountered in the gastrointestinal tract. This included varying concentrations of phosphate with and without acid pre-treatment.

Administration of sevelamer to normal rats produced 90 and 77% increases in fecal excretion of phosphorus in the two experiments. Calcium carbonate produced a 23% increase in fecal phosphorus excretion compared to a 77% increase produced by sevelamer. Decreased urinary phosphorus, indicating decreased absorption of phosphorus was observed in a dose-dependent manner with sevelamer administration. Animals administered a 0.5% dietary mixture had a 57% decrease in total urinary phosphorus, while animals administered 1, 3 and 9% had 66, 88 and 96% decreases in total urinary phosphorus, respectively. The results from these efficacy studies demonstrate that sevelamer is capable of binding dietary phosphorus in normal animals, preventing GI absorption of phosphorus.

**TOXICOLOGY**

RENVELA contains sevelamer, a non-absorbed phosphate binding crosslinked polymer, free of metal and calcium. RENVELA (sevelamer carbonate) was developed as a pharmaceutical alternative to sevelamer hydrochloride (RENAGEL®).

Both sevelamer hydrochloride and sevelamer carbonate salt forms are polymeric anion exchange resins with the same polymeric structure. The amines in the polymer exist in a protonated form and bind to negatively charged phosphates. While the counterions differ for the two salts, the polymer itself, the active moiety responsible for binding of phosphate, remains the same. Since in both resins the active moiety responsible for phosphate binding is the same polymer (sevelamer) and the two salts have been shown to be equivalent both in *in vitro* and *in vivo*, the nonclinical data generated using sevelamer hydrochloride are also applicable to sevelamer carbonate.

**Carcinogenesis**

Standard lifetime carcinogenicity bioassays were conducted in mice and rats. Rats were given sevelamer hydrochloride by diet at 0.3, 1, or 3 g/kg/day. There was an increased incidence of urinary bladder transitional cell papilloma in male rats (3 g/kg/day) at a human equivalent dose 2 times the maximum clinical trial dose of 14.4 g/day. Mice received mean dietary doses of 0.8, 3, or 9 g/kg/day. No increased incidence of tumors was observed in mice at a human equivalent dose 3 times the maximum clinical trial dose of 14.4 g/day.

**Mutagenesis**

A series of genotoxicity studies were performed to assess sevelamer’s mutagenic potential. In the Salmonella typhimurium reverse mutation assay, sevelamer produced the same mean number of revertants as the negative control in all strains tested with and without metabolic activation. Sevelamer is considered to be non-mutagenic. In the *in vitro* mammalian cytogenetics test, sevelamer, at 5 mg/mL, was concluded to be weakly positive for the induction of structural chromosome aberrations and negative for the induction of numerical chromosome aberrations. The weakly positive effects of sevelamer are thought to be due to sevelamer’s ability to absorb
the culture medium and not the direct action of the test article. Sevelamer was tested in the in vivo mouse micronucleus assay to confirm these results. Since sevelamer is non-absorbed, it was injected intraperitoneally to maximize its potential effects. Sevelamer was administered at doses up to 5 g/kg/day for 2 consecutive days. Under the conditions of this study, sevelamer was concluded to be nonclastogenic.

**Impairment of Fertility**

Developmental and reproductive toxicity studies have been performed with sevelamer to assess teratogenic potential and effects on fertility. In the segment I study, sevelamer had no adverse effect upon male and female fertility or on early embryonic development at the highest dose tested (4.5 g/kg/day). In the segment III pre- and post-natal study, there was no evidence of maternal toxicity at any dose level. There was no effect on reproductive performance during gestation, parturition or lactation and no effect on the survival, physical development, behavior and reproductive performance of the F1 generation or on the survival and development of the F2 generation pups at doses tested (≤ 1.0 g/kg/day). In conclusion, no reproductive toxicity has been observed with sevelamer.

**Toxicology**

To assess nonclinical toxicity, sevelamer was administered orally to Sprague-Dawley rats acutely and for 1, 3, and 6 months at doses up to 10 g/kg/day, and to beagle dogs acutely and for 1, 3, and 12 months at doses up to 2 g/kg/day. In general, sevelamer caused minimal toxicity. In rats, sevelamer produced a dose-dependent decrease in fat-soluble vitamin E and decreased levels of fat-soluble vitamin D and vitamin K (measured by coagulation time) at high doses only. Potentially clinically relevant findings (anemia, focal hemorrhages) due to these decreased serum fat-soluble vitamin levels have only been observed in high-dose (4.5 to 10 g/kg/day) male rats.

In the segment II studies in rats and rabbits, there was no evidence that sevelamer directly induced embryolethality, fetotoxicity, or teratogenicity at the highest doses tested (1.0 g/kg/day in rabbits and 4.5 g/kg/day in rats). In rats, at doses of 1.5 and 4.5 g/kg/day (approximately 8 and 20 times the maximum clinical trial dose of 200 mg/kg/day), sevelamer caused reduced or irregular ossification of fetal bones, probably due to a reduced absorption of fat-soluble vitamin D and/or vitamin K depletion at these high doses.

Sevelamer has not been studied in juvenile animals. Its effects on pediatric development are inferred from short-term pediatric clinical studies (see CLINICAL TRIALS, Clinical Study of Sevelamer Carbonate Powder and Tablets in Pediatric Patients).

There are no reported overdoses of sevelamer in patients. Since sevelamer is not absorbed, the risk of systemic toxicity is low.

Studies were conducted with sevelamer carbonate to bridge from the existing toxicology for the hydrochloride salt of sevelamer to the carbonate salt.

To assess nonclinical toxicity, sevelamer hydrochloride and sevelamer carbonate were administered to Sprague Dawley rats and to beagle dogs for four weeks. In rats, two groups received diet mixed with sevelamer carbonate at the dose-level of 1.0 or 4.5 g/kg/day and two
other groups received diet mixed with sevelamer hydrochloride at the dose-level of 1.0 or 4.5 g/kg/day. In dogs, treated animals received either sevelamer carbonate or sevelamer hydrochloride once daily by oral gavage at a dose-level of 0.2 or 1.0 g/kg/day. Other than the reduced serum levels of fat soluble vitamins in rats, no systemic toxicity related to administration of sevelamer carbonate or sevelamer hydrochloride was observed. In addition, these findings were comparable to those seen with similar studies conducted with sevelamer hydrochloride.
REFERENCES


PART III: CONSUMER INFORMATION

RENVELA®
Sevelamer carbonate tablets and powder for oral suspension
This leaflet is part III of a three-part “Product Monograph” published when RENVELA was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about RENVELA. Contact your doctor or pharmacist if you have any questions about the drug.

ABOUT THIS MEDICATION

What the medication is used for:
RENVELA is used to treat high levels of phosphorus in the blood in the following patients who have end-stage renal disease and are undergoing dialysis:
• adults and
• children (6 years of age and older) with a Body Surface Area (BSA) of equal to or greater than 0.75 m²

What it does:
RENVELA is a phosphate binder that is not absorbed in your body. When taken with meals RENVELA inhibits intestinal absorption of ingested phosphate from food.

When it should not be used:
• in patients with low phosphorus levels
• in patients with bowel obstruction/blockage, or with known active damage to the lining of the digestive tract such as necrosis (death of tissue), perforation (hole), ulcers (sores) or bleeding.
• in patients allergic to sevelamer carbonate or one of the other ingredients in the product (See What the nonmedicinal ingredients are).
• in children that are below 6 years of age, have a BSA less than 0.75 m², or that have mild hyperphosphatemia.

What the medicinal ingredient is:
Sevelamer carbonate

What the nonmedicinal ingredients are
Tablets: Diacetylated monoglycerides, hypromellose, iron oxide black, isopropyl alcohol, microcrystalline cellulose, propylene glycol, sodium chloride, zinc stearate.

Powder: Natural and artificial citrus cream flavouring, propylene glycol alginate, sodium chloride, sucralose, and ferric oxide (yellow).

What dosage forms it comes in:
Tablets: 800 mg
Powder: 0.8 g and 2.4 g

WARNINGS AND PRECAUTIONS

SERIOUS WARNING AND PRECAUTION
RENVELA may cause serious side effects that may require hospitalization and surgery. Tell your doctor or go to the hospital right away if you have difficulty swallowing, bowel obstruction, bowel perforation.

BEFORE you use RENVELA talk to your doctor or pharmacist if you:
• have difficulty swallowing (swallowing disorders or problems with your esophagus)
• have an intestinal disorder such as, conditions that slow down the passage of food through the intestine and lead to blockage.
• have had surgery on your intestines.
• have severe or worsening constipation
• have low phosphorus levels in your blood.
• have low calcium levels in your blood.
• are pregnant, plan to become pregnant or are nursing
• have any allergies to this drug or its ingredients or components of the container

INTERACTIONS WITH THIS MEDICATION

RENVELA may affect the way other medicines work. Please tell your doctor or pharmacist what medicine you have recently taken, are taking or intend to take including those available without prescription and herbal remedies. These medicines may need to be taken one hour before or three hours after RENVELA. Remember, RENVELA must always be taken with food.

If you see another doctor or a dentist while you are using RENVELA, you should tell them that you are using RENVELA.

Drugs that may interact with RENVELA include: ciprofloxacin and levothyroxine. Your doctor may order blood tests to more closely monitor the thyroid hormones in your blood if you are taking levothyroxine and RENVELA.

RENVELA may also interact with drugs that are used to prevent the rejection of a transplanted organ, such as cyclosporin, mycophenolate and tacrolimus.

RENVELA may interact with drugs that are used to treat stomach ulcer known as proton pump inhibitors (e.g. pantoprazole, omeprazole).
PROPER USE OF THIS MEDICATION

Tablets and Powder

RENVELA is available as tablets or powder for oral suspension. The powder should be used if you:

- have trouble swallowing the tablets. Talk to your doctor about which one you prefer to take. You can switch between the tablets and powder over the course of your treatment. However you SHOULD NOT mix a tablet and the powder together to get your dose.
- will be giving RENVELA to a small child
- RENVELA should be taken 3 times a day with meals and/or snacks.
- It should ONLY be taken or given to your child with meals or snacks. You SHOULD NOT take it or give it to your child on an empty stomach.
- The total daily dose the doctor tells you to take should be divided between the meals or snacks portions you or your child eats during the day.

**Tablet:** Swallow the tablets whole. DO NOT crush, chew or break the tablet.

**Powder:** Before you can take the powder, it must be mixed:

- in water or (see A))
- in a drink other than water such as ginger ale (see A)) or
- sprinkled on food such as applesauce, whey protein powder or added to lukewarm foods after cooking (up to 50°C) such as oatmeal, scrambled eggs and baked boneless-skinless chicken breast (see B))

More than one sachet can be taken at the same time as long as the minimum amount of water or food is used for each sachet.

The powder DOES NOT dissolve. It should be stirred vigorously just before you or your child drinks it.

Once mixed in water or a drink or added to food, it should be taken within 30 minutes. It is important to drink all of the liquid or eat the entire food to ensure that all of the powder is taken.

DO NOT:

- take RENVELA as a dry powder or
- heat the powder (put it in the microwave or other heat source) or
- add it to hot foods or liquids

Usual starting dose:

Your doctor will:

- determine your dose based on your phosphorus levels
- determine your child’s dose based on their Body Surface Area
- monitor your and your child’s phosphorus levels and change the dose as needed

Take it exactly as directed by your doctor.

Instructions on How to Use the Powder:

RENVELA is only available in 0.8 g and 2.4 g sachets.

Before opening the sachets:

- hold the top corner of the sachet and shake it to move the powder to the bottom
- open it by tearing along the marked line

A) How to prepare a dose in water or in a drink other than water such as ginger ale

<table>
<thead>
<tr>
<th>Strength</th>
<th>Minimum amount of liquid to be mixed for each sachet</th>
<th>mL</th>
<th>tablespoon</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.8 g (use entire sachet)</td>
<td>30</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>2.4 g (use entire sachet)</td>
<td>60</td>
<td>4</td>
<td></td>
</tr>
</tbody>
</table>

B) How to prepare a dose when added to food

<table>
<thead>
<tr>
<th>Strength</th>
<th>Minimum amount of food to be used for each sachet</th>
<th>mL</th>
<th>tablespoons</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.8 g (use entire sachet)</td>
<td>120</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>2.4 g (use entire sachet)</td>
<td>120</td>
<td>8</td>
<td></td>
</tr>
</tbody>
</table>

In some cases, your doctor may recommend 0.4 g dose adjustments for your child to get the correct dose. Since RENVELA is not available in a 0.4 g sachet, you will need to measure some powder from a 0.8 g sachet to get the 0.4 g dose (see C) and D)).

C) How to measure 0.4 g of powder from a 0.8 g sachet

Use a measuring spoon to measure the correct amount of powder for your 0.4 g dose. DO NOT tap the measuring spoon to compact the powder.

<table>
<thead>
<tr>
<th>Strength</th>
<th>Amount of powder to be taken from a 0.8 g sachet</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.4 g</td>
<td>1 mL or ¼ teaspoon</td>
</tr>
</tbody>
</table>

- Close the 0.8 g sachet by folding it over twice
The remaining powder may be used within 24 hours for the next dose.
Throw away the sachet if it has been left opened for more than 24 hours and use a new one.

D) How to prepare a 0.4 g dose in water or in a drink other than water such as ginger ale or if added to food

<table>
<thead>
<tr>
<th>Strength</th>
<th>Minimum amount of liquid to be mixed</th>
<th>Minimum amount of food to be used</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>mL</td>
<td>tablespoons</td>
</tr>
<tr>
<td>0.4 g</td>
<td>30</td>
<td>2</td>
</tr>
</tbody>
</table>

**Overdose:**
In case of an overdose, contact your doctor or regional poison control center immediately.

**Missed Dose:**
If a dose is forgotten, it should be skipped. Double dosing is not advisable.

**SIDE EFFECTS AND WHAT TO DO ABOUT THEM**

Although RENVELA is generally well tolerated, some patients may experience side effects, including: nausea, vomiting, diarrhea, indigestion, constipation, abdominal pain, rash, itch, and flatulence (gas). Tell your doctor if you have new onset or worsening of constipation.

Contact your doctor if you experience severe abdominal pain, stomach or intestine problems, or blood in the stool. These symptoms can be due to serious inflammatory bowel disease caused by crystal deposits in your bowel. Your doctor will decide whether or not you should continue treatment with RENVELA.

**SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM**

<table>
<thead>
<tr>
<th>Symptom / effect</th>
<th>Talk with your doctor or pharmacist</th>
<th>Stop taking drug and call your doctor or pharmacist</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Only if severe</td>
<td>In all cases</td>
</tr>
<tr>
<td><strong>Bowel Obstruction (ileus), Intestinal Blockage or, hole in the intestine:</strong> sudden abdominal pain, inflammation and ulcers, abdominal discomfort, cramping and gas pains, diarrhea or difficulty passing stools, bleeding (blood in stools), nausea/vomiting especially after meals, excessive burping, loss of appetite; later symptoms include fever and chills</td>
<td>✅</td>
<td></td>
</tr>
<tr>
<td><strong>Unknown</strong></td>
<td>Diverticulitis: left lower quadrant pain, fever, nausea, diarrhea, or constipation</td>
<td>✅</td>
</tr>
<tr>
<td></td>
<td>Allergic reactions: rash, swelling of the face or mouth, difficulty breathing.</td>
<td>✅</td>
</tr>
<tr>
<td></td>
<td>Inflammation of the bowel: Severe abdominal pain, stomach or intestine problems, blood in the stool</td>
<td>✅</td>
</tr>
</tbody>
</table>

This is not a complete list of side effects. For any unexpected effects while taking RENVELA, contact your doctor or pharmacist.

**HOW TO STORE IT**

Store the tablets and powder at controlled room temperature 15°C to 30°C. Protect from moisture and heat.

Keep out of reach and sight of children.
Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:
- for information on how to report online, by mail or by fax;
  or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website (https://health-products.canada.ca/dpd-bdpp/index-eng.jsp); the manufacturer’s website www.sanofi.ca, or by calling 1-800-265-7927.

This leaflet was prepared by sanofi-aventis Canada Inc.

Last revised: October 29, 2020